8 Ways to Create Value in Cancer Care

Slideshow

This slide show features 8 ways oncologists can create value in cancer care, from building a great team of staff members to staying on top of the latest developments in your field.

References:

1. Krasner MS; Epstein RM, Beckman H, et al. Association of an educational program in mindful communication with burnout, empathy, and attitudes among primary care physicians. JAMA. 2009;302:1284-93.Read here.

Recent Videos
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
2 experts are featured in this series.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Related Content
The addition of pelareorep to standard-of-care therapy in patients with KRAS-mutated microsatellite-stable CRC exhibited an ORR of 33%.

Pelareorep Exhibits Activity in Second-Line KRAS-Mutated Metastatic CRC

Roman Fabbricatore
December 16th 2025
Article

The addition of pelareorep to standard-of-care therapy in patients with KRAS-mutated microsatellite-stable CRC exhibited an ORR of 33%.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Among the 12 patients with suspected brain metastases treated with RAD 101, the images showed metabolic activity in brain metastases compared with MRI findings.

RAD 101 Imaging Agent Achieves Concordance with MRI in Suspected Brain Mets

Tim Cortese
December 16th 2025
Article

Among the 12 patients with suspected brain metastases treated with RAD 101, the images showed metabolic activity in brain metastases compared with MRI findings.

Why Sexual and Gender Minority Care Is an Oncologic Imperative

Why Sexual and Gender Minority Care Is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO; and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

Atezolizumab/NAT May Impact Fertility in TNBC

Atezolizumab/NAT May Impact Fertility in TNBC

Silas Inman
December 16th 2025
Article

Atezolizumab plus neoadjuvant therapy was found to increase chemotherapy-induced ovarian failure among patients with TNBC.

Data from SERENA-6 showed delayed disease progression and deterioration in QOL among patients who switched to camizestrant plus CDK4/6 inhibition.

Switching to Camizestrant Combo Improves PFS in HR+/HER2– Breast Cancer

Caroline Seymour
December 15th 2025
Article

Data from SERENA-6 showed delayed disease progression and deterioration in QOL among patients who switched to camizestrant plus CDK4/6 inhibition.